Asian Scientist (Oct. 9, 2013) – Takeda Pharmaceutical Company will partner the newly formed Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) in early-stage drug discovery.
The new institute was formed as a partnership between three New York-based institutions in the United States: Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College.
The institute aims to more effectively translate discoveries in basic science into therapeutics in the clinic. Its focus is on the early stages of developing compounds for “proof of concept” studies.
The partnership with Takeda, a global pharmaceutical company with a strong record of bringing new medicines to market, will benefit drug discovery work at all three institutions.
“Drug discovery is a remarkably complex undertaking that constantly pushes at the frontiers of science,” said Dr. Tadataka Yamada, Takeda’s director and chief medical and scientific officer. “This industry-academic partnership will combine the spirit of innovation in academia with the resources and talents of industry, and we are confident it will lead to remarkable new insights.”
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.